Hepatitis E Virus Antibodies in Patients with Chronic Liver Disease

Autor: Muslim Atiq, Norah J. Shire, Anna Barrett, Susan D. Rouster, Kenneth E. Sherman, Mohamed T. Shata

Publikováno v: Emerging Infectious Diseases, Vol 15, Iss 3, Pp 479-481 (2009)

In the United States, the seroprevalence rate for hepatitis E virus (HEV) is ≈20%. This study examined HEV seroprevalence in persons with and without chronic liver disease. Our data indicate that HEV seropositivity is high in patients with chronic

Externí odkaz: https://doaj.org/article/c247c17edcd84830a1e7838691d81583

PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

Autor: Elizabeth Hedgeman, Jon P. Fryzek, Lars Pedersen, Deirdre Cronin-Fenton, Mette Nørgaard, Torben Riis Rasmussen, Naimisha Movva, Tapashi Dalvi, Stephen Hamilton-Dutoit, Hanh Hansen, Anders Mellemgaard, Norah J. Shire

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, 16892 . https://doi.org/10.1038/s41598-021-96486-2
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, pp. 16892 . https://doi.org/10.1038/s41598-021-96486-2
Scientific Reports

Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c714e5100877d9c2cba31cc1cb53eae7
https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b9

Fine‐Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection

Autor: Iain P. Fraser, Larissa Wenning, Eric Mangin, Bonnie J. Howell, Christine Fandozzi, Jill Maxwell, W. Gao, Radha Railkar, Kristien Van Dyck, Chris Chung, Norah J. Shire, Andrew H. Talal, Melanie Anderson, Luzelena Caro, Serghei Popa, Andrea L. Webber, André M. M. Miltenburg, S. Aubrey Stoch

Publikováno v: Clinical Pharmacology & Therapeutics. 107:1325-1333

Fine-needle aspiration (FNA) for serial hepatic sampling may be an efficient and less invasive alternative to core needle biopsy (CNB), the current standard for liver tissue sampling. In this randomized, open-label trial in 31 participants with hepat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8504ae5549bfbd91fd93b738af6db4b
https://doi.org/10.1002/cpt.1737

Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark

Autor: Mette Nørgaard, Torben Riis Rasmussen, Norah J. Shire, Hanh Hansen, Anders Mellemgaard, Anita Midha, Jill Walker, Elizabeth Hedgeman, Lars Pedersen, Tapashi Dalvi, Deirdre Cronin-Fenton, Stephen Hamilton-Dutoit, J. Rigas, Anne-Marie Boothman, Jon P. Fryzek

Publikováno v: Hedgeman, E, Nørgaard, M, Dalvi, T, Pedersen, L, Hansen, H P, Walker, J, Midha, A, Shire, N, Boothman, A-M, Fryzek, J P, Rigas, J, Mellemgaard, A, Rasmussen, T R, Hamilton-Dutoit, S & Cronin-Fenton, D 2021, ' Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark ', Cancer epidemiology, vol. 73, pp. 101976 . https://doi.org/10.1016/j.canep.2021.101976
Hedgeman, E, Nørgaard, M, Dalvi, T, Pedersen, L, Hansen, H P, Walker, J, Midha, A, Shire, N, Boothman, A M, Fryzek, J P, Rigas, J, Mellemgaard, A, Rasmussen, T R, Hamilton-Dutoit, S & Cronin-Fenton, D 2021, ' Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark ', Cancer epidemiology, vol. 73, 101976 . https://doi.org/10.1016/j.canep.2021.101976

BACKGROUND: PD-L1 expression on tumor cells (TCs) or immune cells (ICs) may be used as a prognostic marker for survival in patients with NSCLC. We characterized PD-L1 expression on TCs or ICs in a patient cohort with NSCLC to determine associations b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46578e6da5a61a4e3e492aa29027f4dc
https://pure.au.dk/portal/da/publications/programmed-cell-death-ligand1-expression-and-survival-in-a-cohort-of-patients-with-nonsmall-cell-lung-cancer-receiving-firstline-through-thirdline-therapy-in-denmark(d9615987-9773-43dc-9b60-de7ac1e0059e).html

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Autor: Marina Chiara Garassino, J.H. Ji, Nikunj Patel, Y. Chen, Jonathan W. Goldman, György Losonczy, Norah J. Shire, Galina Statsenko, Katsuyuki Hotta, Haiyi Jiang, Oleksandr Voitko, Libor Havel, D. Trukhin, Maximilian Hochmair, Peter J. Laud, Mikhail Dvorkin, A. Poltoratskiy, Niels Reinmuth, Luis Paz-Ares, Mustafa Ozguroglu

OZGUROGLU, MUSTAFA/0000-0002-8417-8628 WOS:000579504300008 PubMed ID: 32961445 Objectives: In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf33c41b74bbe8b2dd8b0bf98d18cb3d
https://eprints.whiterose.ac.uk/166497/3/PIIS0169500220306000.pdf